注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Intellia Therapeutics Inc是一家临床阶段的基因组编辑公司。该公司专注于使用成簇规律间隔的短回文重复序列(CRISPR)/CRISPR相关9(Cas9)技术开发治疗性疗法。CRISPR/Cas9是一种基因组编辑技术,即改变基因组脱氧核糖核酸(DNA)选定序列的过程。其专注于利用其模块化平台来推进对高度未满足需求的疾病的体内和体外治疗。其主要体内候选药物NTLA-2001用于治疗转甲状腺素蛋白(ATTR)淀粉样变性,以及NTLA-2002用于治疗遗传性血管性水肿(HAE)。该公司正在开发体外应用以解决免疫肿瘤学和自身免疫性疾病。其先进的体外项目包括全资持有的T细胞受体(TCR)-T细胞候选药物NTLA-5001,用于治疗急性髓性白血病(AML)和用于治疗镰状细胞病的造血干细胞(HSC)。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Franciscus A. G. M. Verwiel | 59 | 2017 | Independent Chairman of the Board |
John M. Leonard | 64 | 2014 | President, CEO & Director |
Andrew May | - | - | Founder and Member of Scientific Advisor Board |
Nessan Bermingham | 50 | 2014 | Founder & Member of Scientific Advisor Board |
Rodolphe Barrangou | - | - | Founder & Member of Scientific Advisor Board |
Derrick J. Rossi | - | 2015 | Founder & Member of Scientific Advisor Board |
Erik J. Sontheimer | - | - | Founder & Member of Scientific Advisor Board |
Luciano Marraffini | - | - | Founder & Member of Scientific Advisor Board |
Arthur M. Krieg | 66 | - | Member of Scientific Advisory Board |
Jesse L. Goodman | 71 | 2018 | Independent Director |
Georgia Keresty | 61 | 2021 | Independent Director |
Muna Bhanji | 60 | 2022 | Independent Director |
Beverly L. Davidson | - | 2015 | Member of Scientific Advisory Board |
Fred E. Cohen | 67 | 2019 | Independent Director |
William J. Chase | 55 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核